Swaziland Integrated HIV Management Guidelines

Last updated
Friday, February 4, 2022 - 16:25

About this Guideline:

These guidelines address new innovations like HIV self-testing (HIVST), Pre-Exposure Prophylaxis (PrEP) for HIV prevention, a package of care for clients with advanced immunodeficiency and the introduction of better drugs and formulations (e.g. tenofovir, lamivudine, dolutegravir (TLD) a fixed dose combination (FDC) formulation) including differentiated ART delivery models (CommART). The guidelines will also bring clarity on quality related issues like re-testing for verification for clients who are initiating on ART and guidance to strengthen pharmacovigilance systems.

These guidelines provide the standards and recommendations to move Swaziland forward in achieving the Government of the Kingdom of Swaziland’s vision of zero new HIV infections (including elimination of Mother to Child Transmission of HIV) and ending AIDS. To achieve this vision we need a continued concerted effort from all stakeholders at all levels of service delivery to translate these guidelines into action.

Content rating